The report includes an in-depth analysis of the U.S. Uterine Fibroids Treatment Devices Market, including market size and trends, product mix, Applications, and supplier analysis. The market for uterine fibroids treatment devices in the U.S. was valued at approximately USD 2.93 billion in 2024 and is expected to expand at a compound annual growth rate (CAGR) of 9.52% from 2025 to 2034. This anticipated growth is largely due to the increasing number of women diagnosed with uterine fibroids, especially within the 30 to 50 age demographic. Additionally, advancements in non-invasive and minimally invasive treatment devices have enhanced the market's potential. Innovative technologies, including ultrasound and radiofrequency ablation, have led to improved patient outcomes and reduced recovery times.

The surgical techniques segment led the market in 2024, mainly due to the rising number of women with uterine fibroids, which highlights the need for effective surgeries. Improvements in surgical technology have made procedures safer and more precise, appealing to both healthcare providers and patients. Increased awareness of treatment options has encouraged more women to consider surgical solutions, boosting this segment's performance. The ablation techniques segment is expected to grow the fastest in the U. S. treatment devices industry for uterine fibroids. This growth is driven by demand for minimally invasive options that offer advantages like less pain, shorter hospital stays, and quicker recovery times compared to traditional surgeries. The rise in chronic conditions needing ablation procedures also supports this trend.

In 2024, the invasive treatment segment led the market for uterine fibroid treatments due to the effectiveness of surgical options like myomectomy and hysterectomy. Many patients and doctors choose these definitive treatments for large or painful fibroids, which provide high success rates and significant symptom relief. Healthcare facilities are also investing in advanced technologies, which is expected to improve the quality and outcomes of these invasive procedures. On the other hand, the non-invasive treatment segment is projected to grow the fastest. This is because more patients prefer options that lessen recovery time and discomfort. Increased awareness and technological advancements have made non-invasive treatments more effective and accessible, leading to higher demand among women. This trend is likely to expand the market share of non-invasive treatments.

The Midwest has emerged as the leading area in the U.S. uterine fibroids treatment devices market in 2024. This region has a significant patient population suffering from uterine fibroids, particularly among African American women, who are disproportionately affected by this condition. The growing number of diagnosed cases has heightened the demand for effective and minimally invasive treatment solutions, thereby propelling the market for uterine fibroids treatment devices.

Key players in the market are implementing various strategies, including product launches and approvals, to enhance their market presence and gain a competitive edge over other participants. These developments are expected to drive market growth throughout the forecast period. Notable market players include Medtronic, Stryker, Boston Scientific Corporation, Insightec, CooperSurgical Inc, and Hologic, Inc, among others.